HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Rhea-AI Summary
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) announced that China’s NMPA has granted conditional approval for ATLED® (fanregratinib, HMPL-453), a novel oral FGFR 1/2/3 inhibitor, to treat adult patients in China with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement after prior systemic therapy.
The approval is based on a pivotal Phase II registration cohort in China (NCT04353375), which showed an IRC-assessed objective response rate of 42.5%, median duration of response of 6.9 months, disease control rate of 83.9%, median progression-free survival of 6.9 months and median overall survival of 16.6 months. Median time to response was 1.4 months. Enrollment for a Phase IIIb confirmatory study began in January 2026, and HUTCHMED plans to commercialize ATLED® in China using its existing infrastructure while retaining worldwide rights to fanregratinib.
Positive
- NMPA conditional approval in China for ATLED® in FGFR2-altered advanced ICC after prior systemic therapy
- Objective response rate 42.5% in Phase II registration cohort for FGFR2-fusion/rearrangement ICC
- Disease control rate 83.9% with median duration of response 6.9 months in treated patients
- Median overall survival 16.6 months and median progression-free survival 6.9 months in the Phase II cohort
- Rapid median time to response of 1.4 months in pretreated advanced ICC patients
- HUTCHMED retains all global rights to fanregratinib, preserving future partnership or commercialization options
Negative
- China NMPA approval for ATLED® is conditional, pending confirmation from the ongoing Phase IIIb study initiated January 2026
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 16 | Phase III clinical data | Positive | +3.0% | SAFFRON showed significant progression-free and overall survival improvements versus chemotherapy. |
| Jul 30 | Interim results | Neutral | -5.4% | Revenue was broadly unchanged despite oncology sales growth and reported net income. |
| Jul 02 | NMPA approval | Positive | +6.1% | ORPATHYS received conditional approval for MET-amplified gastric cancer. |
| Jun 30 | Earnings-date notice | Neutral | +0.5% | HUTCHMED scheduled its 2026 half-year financial-results announcement. |
| Jun 24 | Phase II clinical data | Positive | +0.2% | Fanregratinib data showed response and survival measures in pretreated ICC. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory announcements generally aligned with gains, while the interim-results announcement diverged with a -5.44% reaction.
Key Terms
nmpa regulatory
objective response rate medical
disease control rate medical
progression-free survival medical
overall survival medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion or rearrangement who have previously received systemic therapy. Fanregratinib will be marketed in China under the brand name ATLED®.
ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2
The approval is supported by data from the Phase II registration cohort of the single-arm, multi-center, open-label, pivotal Phase II/IIIb clinical trial of ATLED® in China (NCT04353375). The results were recently presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026. The study met its primary endpoint, demonstrating an Independent Review Committee (IRC)-assessed objective response rate (ORR) of
Key secondary endpoints showed consistent clinical activity and a rapid onset of action, with a median time to response of 1.4 months. Median duration of response (DoR) was 6.9 months (
“As a major and devastating subtype of primary liver cancer, intrahepatic cholangiocarcinoma carries an immense disease burden with historically limited targeted options. We are thrilled by the NMPA approval of ATLED®, which directly addresses this critical therapeutic gap in China,” said Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED. “This approval unlocks an important new treatment alternative for a substantial population of pretreated advanced ICC patients. We are fully prepared to leverage our established commercial infrastructure to bring this precision medicine to patients as rapidly as possible.”
The Phase IIIb portion of the trial will serve as the confirmatory study to further validate the clinical benefits and safety of ATLED® in this setting. Enrollment for this confirmatory cohort was initiated in January 2026.
About ATLED®
ATLED® (fanregratinib, HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of fanregratinib, the further clinical development for fanregratinib, its expectations as to whether any studies on fanregratinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fanregratinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in other jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of fanregratinib for a targeted indication; and HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans for fanregratinib, and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |
_____________________________
REFERENCES
| 1 | Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition). Chin J Clin Med. 2025;32(1):1-18. |
| 2 | Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34. |
| 3 | Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10. |
